Ursofalk - instructions for use, analogs, reviews and release forms (capsules or tablets 250 mg, suspension or syrup) drugs for the treatment of cirrhosis and jaundice in adults, children (including newborns) and pregnancy. Composition

In this article, you can read the instructions for using the drug Ursofalk. Comments of visitors to the site - consumers of this medication, as well as opinions of doctors of experts on the use of Ursofalk in their practice are presented. A big request is to actively add their feedback on the drug: the medicine helped or did not help get rid of the disease, which were observed complications and side effects, possibly not declared by the manufacturer in the annotation. Analogues of Ursofalk in the presence of existing structural analogues.Use for the treatment of cirrhosis of the liver and jaundice in adults, children (including infants and newborns), as well as during pregnancy and lactation. Composition of the preparation.

Ursofalk hepatoprotector. Has choleretic effect. Reduces the synthesis of cholesterol in the liver, its absorption in the intestine and concentration in the bile, increases the solubility of cholesterol in the bile excretory system, stimulates the formation and excretion of bile. Reduces the lithogenicity of bile, increases the content of bile acids. Causes an increase in gastric and pancreatic secretion, increases the activity of lipase. Has hypoglycemic effect.

Causes partial or complete dissolution of cholesterol stones when ingested, reduces the saturation of bile with cholesterol, which promotes the mobilization of cholesterol from gallstones.

It has an immunomodulatory effect, affects immunological reactions in the liver: reduces the expression of certain antigens on the hepatocyte membrane, affects the number of T-lymphocytes, the formation of interleukin-2, reduces the number of eosinophils.

Composition

Ursodeoxycholic acid + auxiliary substances.

Indications

• dissolution of gallstones cholesterol stones;
• biliary reflux-gastritis;
• primary biliary cirrhosis in the absence of signs of decompensation (symptomatic treatment).

Forms of release

Capsules 250 mg (sometimes mistakenly called pills).

Suspension for oral administration (sometimes mistakenly referred to as syrup).

Instructions for use and dosage

Children and adults weighing less than 34 kg are advised to use Ursofalk in the form of a suspension.

To dissolve cholesterol gallstones, a dose of 10 mg / kg of body weight is administered once a day.

The following dosing regimen is recommended:

Capsules

• body weight up to 60 kg - 2 capsules per day;
• body weight 61-80 kg - 3 capsules per day;
• body weight 81-100 kg - 4 capsules per day;
• body weight over 100 kg - 5 capsules per day.

Suspension for oral administration

• body weight 5-7 kg - number of measuring spoons 0.25 per day;
• body weight 8-12 kg - number of measuring spoons 0.50 per day;
• body weight 13-18 kg - the number of measuring spoons is 0.75 per day;
• body weight 19-25 kg - number of measuring spoons 1 per day;
• body weight 26-35 kg - number of measuring spoons 1.5 per day;
• body weight 36-50 kg - number of measuring spoons 2 per day;
• body weight 51-65 kg - number of measuring spoons 2.5 per day;
• body weight 66-80 kg - number of measuring spoons 3 per day;
• body weight 81-100 kg - number of measuring spoons 4 per day;
• body weight over 100 kg - the number of measuring spoons 5 per day.

The drug should be taken daily in the evening, before going to bed (capsules are not chewed), squeezed with a small amount of liquid.

Duration of treatment is 6-12 months. For the prevention of repeated cholelithiasis, the use of the drug is recommended for several months after the dissolution of the stones.

For the treatment of biliary reflux gastritis, 1 capsule (1 measuring spoon) of Ursofalk is prescribed daily in the evening before going to bed, washing with a little water. The course of treatment - from 10-14 days to 6 months, if necessary - up to 2 years.

For symptomatic treatment of primary biliary cirrhosis, the daily dose depends on the body weight and is from 2 to 6 capsules (measuring spoons) (about 10-15 mg / kg body weight).

The following dosing regimen is recommended:

Capsules

• body weight 34-50 kg - 2 capsules per day;
• body weight 51-65 kg - 3 capsules per day;
• body weight 66-85 kg - 4 capsules per day;
• body weight 86-110 kg - 5 capsules per day;
• body weight over 110 kg - 6 capsules per day.

Suspension for oral administration

• body weight 5-7 kg - number of measuring spoons 0.25 per day;
• body weight 8-12 kg - number of measuring spoons 0.5 per day;
• body weight 13-18 kg - the number of measuring spoons is 0.75 per day;
• body weight 19-25 kg - number of measuring spoons 1 per day;
• body weight 26-35 kg - number of measuring spoons 1.5 per day;
• body weight 36-50 kg - number of measuring spoons 2 per day;
• body weight 51-65 kg - number of measuring spoons 3 per day;
• body weight 66-80 kg - number of measuring spoons 4 per day;
• body weight 81-100 kg - number of measuring spoons 5 per day;
• body weight over 100 kg - the number of measuring spoons 6 per day.

Side effect

• diarrhea;
• nausea;
• pain in the epigastric region and right hypochondrium;
• calcification of gallstones;
• allergic reactions.

Contraindications

• X-ray positive (high in calcium) gallstones;
• non-functioning gallbladder;
• acute inflammatory diseases of the gallbladder, bile ducts and intestines;
• cirrhosis of the liver in the stage of decompensation;
• severe renal dysfunction;
• severe liver dysfunction;
• pronounced impairment of pancreatic function;
• pregnancy;
• lactation period (breastfeeding);
• hypersensitivity to the components of the drug.

Application in pregnancy and lactation

The drug is contraindicated in pregnancy and lactation (breastfeeding).

Use in children

Possibly, according to the dosing regimen.

special instructions

In cholelithiasis, treatment effectiveness is monitored every 6 months by X-ray and ultrasound examination of the biliary tract to prevent relapse of cholelithiasis.

When cholestatic liver diseases should periodically determine the activity of transaminases, alkaline phosphatase and gamma-glutamyltranspeptidase in the blood serum.

In the treatment of primary biliary cirrhosis, transient decompensation of liver cirrhosis can occur, which disappears after drug withdrawal.

During treatment, women of childbearing age should use reliable methods of contraception.

Drug Interactions

Colestramine, colestipol and antacids, containing aluminum hydroxide or smectite (aluminum oxide), reduce the absorption of ursodeoxycholic acid in the intestine and thus reduce its absorption and efficacy. If the use of drugs containing at least one of these substances is still necessary, they must be taken at least 2 hours before taking Ursofalk.

Ursodeoxycholic acid can enhance the absorption of cyclosporine from the intestine.Therefore, in patients taking cyclosporine, the doctor should check the concentration of cyclosporine in the blood and adjust the dose of cyclosporine, if necessary.

In some cases, Ursofalk can reduce the absorption of ciprofloxacin.

Lipid-lowering drugs (especially clofibrate), estrogens, neomycin or progestins increase the saturation of bile with cholesterol and may reduce the ability to dissolve cholesterol bile stones.

Analogues of medicinal product Ursofalk

Structural analogs for the active substance:

• Livedoksa;
• Urdoks;
• Urso 100;
• Ursodez;
• Ursodeoxycholic acid;
• Ursodex;
• Ursuliv;
• Ursoron Rompharm;
• Ursor C;
• Ursosan;
• Holudexan;
• Exxhol.

Similar medicines:

Other medicines: